Novartis caught in the Stormy Daniels affair, after huge payment to Trump’s lawyer
May 9, 2018Medical Communications, Research and Development Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
All eyes on dry eye disease
May 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing TopiVert, dry eye disease, eye, pharma
Dr Matthew Fyfe, Head of Chemistry and Intellectual Property at TopiVert, gives an illuminating look into the latest developments in …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
J&J’s ketamine-based antidepressant showed mixed success at Phase 3
May 8, 2018Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma
Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …
Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma
May 8, 2018Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma
Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
AstraZeneca jettisons schizophrenia drug for $538 million
May 8, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia
AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …
It’s official: Takeda to buy Shire for £46 billion
May 8, 2018Manufacturing and Production, Sales and Marketing Shire, Takeda, acquisition, pharma
After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Los Angeles becomes latest US city to sue pharma over opioid crisis
May 4, 2018Medical Communications, Sales and Marketing Los Angeles, opioid crisis, pharma
The city of Los Angeles has levied legal action against a number of pharmaceutical firms for their role in advancing …
Mallinckrodt gets two thumbs down from FDA for jaundice drug
May 4, 2018Medical Communications, Sales and Marketing InfaCare, Mallinckrodt, biotech, drugs, pharma, pharmaceutical
Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …
Free webinar – Rational EU risk management for oncology medicines
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA Group, biotech, drugs, pharma, pharmaceutical
It is timely to reflect on how we can best implement the revised GVP module (V) concerning risk management in …
BMS looks to leverage real-world data, with Flatiron collab
May 3, 2018Medical Communications, Sales and Marketing Bristol-Myers Squibb, Flatiron health, biotech, drugs, pharma, pharmaceutical
Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …
The UK sugar tax: A sweet or sour move?
May 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, obesity, pharma, sugar tax
Dr Daniel Bailey, Senior Lecturer in Health, Nutrition and Exercise at the University of Bedfordshire, discusses the benefits of the …
New study argues the importance of existing anti-inflammatory drugs in fighting dementia
May 3, 2018Research and Development Alzheimer's, dementia, pharma
Research into dementia has waned in recent times as researchers struggle to pin down concrete advancements, leading to the withdrawal …
Recreational drug MDMA proves efficacy in reducing PTSD symptoms, new study finds
May 3, 2018Research and Development MDMA, PTSD, pharma
Promising new findings have been revealed in the efficacy of MDMA in treating post-traumatic stress disorder (PTSD).
Speakers Announced for Veeva R&D Summit, Europe
May 3, 2018Medical Communications biotech, drugs, pharma, pharmaceutical, veeva
In the pharma industry, we tend to use a lot of acronyms. Even in every day life, we are shortening …
Sandoz US woes continue with biosimilar rejection
May 3, 2018Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …
450,000 missed breast cancer screenings, 270 lives potentially shortened
May 2, 2018Medical Communications Jeremy Hunt, NHS, UK, biotech, drugs, pharma, pharmaceutical
An error in the automated system left 450,000 women without an invite for breast screening and Jeremy Hunt, the UK’s …
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
May 2, 2018Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
